^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Loqtorzi (toripalimab-tpzi)

    i
    Other names: JS001, JS-001, JS 001, TAB-001, TAB001, terepril monoclonal antibody, treipril monoclonal antibody, TAB 001
    Company:
    Apotex, Coherus Oncology, Dr. Reddy’s, Excellmab, Hikma, LEO Pharma, Shanghai Junshi Biosci
    Drug class:
    PD1 inhibitor
    Related drugs:
    22h
    STC-15-24202: STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas (clinicaltrials.gov)
    P1/2, N=107, Recruiting, STORM Therapeutics LTD | N=188 --> 107 | Trial completion date: Jun 2027 --> Jun 2028 | Trial primary completion date: Dec 2026 --> Dec 2027
    Enrollment change • Trial completion date • Trial primary completion date
    |
    Loqtorzi (toripalimab-tpzi) • STC-15
    5d
    IPG7236 Combined With Toripalimab in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=52, Not yet recruiting, Nanjing Immunophage Biotech Co., Ltd
    New P1/2 trial
    |
    CCR8 (C-C Motif Chemokine Receptor 8)
    |
    Loqtorzi (toripalimab-tpzi) • IPG7236
    5d
    ZM008-001: This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=100, Recruiting, Zumutor Biologics Inc. | N=33 --> 100
    Enrollment change
    |
    Loqtorzi (toripalimab-tpzi) • ZM008
    6d
    STARS-RC10: Efficacy and Safety Comparison of Short-course Radiotherapy Followed by CapeOX Chemotherapy Plus Toripalimab With or Without Concurrent Surufatinib in Neoadjuvant Therapy for Mid-to-low Localized Rectal Cancer of High-risk Criteria (clinicaltrials.gov)
    P2/3, N=212, Recruiting, The First Hospital of Jilin University
    New P2/3 trial
    |
    Loqtorzi (toripalimab-tpzi) • capecitabine • oxaliplatin • Sulanda (surufatinib)
    7d
    LM-101, an anti-SIRPα antibody, in patients with relapsed/refractory lymphoma and advanced head and neck cancer: an open-label, multicenter, phase 1 trial. (PubMed, Clin Cancer Res)
    LM-101 was well tolerated. The preliminary efficacy signal supports further evaluation of LM-101 plus rituximab in relapsed/refractory lymphoma.
    P1 data • Journal
    |
    SIRPA (Signal Regulatory Protein Alpha)
    |
    Rituxan (rituximab) • Loqtorzi (toripalimab-tpzi) • LM-101
    8d
    CHS-114-102: A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=154, Recruiting, Coherus Oncology, Inc. | Trial completion date: May 2027 --> Jan 2028 | Trial primary completion date: May 2027 --> Jan 2028
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • BRAF (B-raf proto-oncogene) • MSI (Microsatellite instability)
    |
    BRAF V600E • BRAF V600 • RAS wild-type
    |
    cisplatin • 5-fluorouracil • Loqtorzi (toripalimab-tpzi) • tagmokitug (CHS-114)
    8d
    Fasting-Mimicking Diet Combined With IO-TKI Combination Therapy in Patients With Metastatic Renal Cell Carcinoma (clinicaltrials.gov)
    P=N/A, N=43, Not yet recruiting, Qilu Hospital of Shandong University
    New trial
    |
    Loqtorzi (toripalimab-tpzi) • axitinib
    10d
    Study on the Efficacy and Safety of JSKN016 as Neoadjuvant Therapy in Resectable Stage II-III Non-small Cell Lung Cancer Patients (clinicaltrials.gov)
    P2, N=54, Not yet recruiting, Shanghai Pulmonary Hospital, Shanghai, China
    New P2 trial
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    EGFR L858R • EGFR exon 19 deletion • ALK fusion
    |
    carboplatin • Loqtorzi (toripalimab-tpzi)
    17d
    A Study Evaluating the Safety and Efficacy of JS212 Combination Therapy in Patients With Advanced Esophageal Squamous Cell Carcinoma (clinicaltrials.gov)
    P2, N=280, Not yet recruiting, Shanghai Junshi Bioscience Co., Ltd.
    New P2 trial
    |
    5-fluorouracil • Loqtorzi (toripalimab-tpzi)
    18d
    SRF114-101: Study of CHS-114 in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=87, Recruiting, Coherus Oncology, Inc. | Trial completion date: Feb 2026 --> Jan 2027 | Trial primary completion date: Feb 2026 --> Sep 2026
    Trial completion date • Trial primary completion date • First-in-human
    |
    Loqtorzi (toripalimab-tpzi) • tagmokitug (CHS-114)
    20d
    KC1036 in Combination With PD-1 Antibody and Platinum-based Chemotherapy for First-line Advanced Esophageal Cancer (clinicaltrials.gov)
    P2, N=60, Recruiting, Beijing Konruns Pharmaceutical Co., Ltd.
    New P2 trial
    |
    cisplatin • paclitaxel • Loqtorzi (toripalimab-tpzi) • KC1036
    20d
    A Phase II Clinical Study Evaluating the Safety, Tolerability,Pharmacokinetics, and Preliminary Efficacy of JS212 andJS213 as Monotherapy and in Combination in Patients Withadvanced Malignant Solid Tumors (clinicaltrials.gov)
    P2, N=480, Not yet recruiting, Shanghai Junshi Bioscience Co., Ltd.
    New P2 trial
    |
    Loqtorzi (toripalimab-tpzi) • AWT020